Femasys FY25 net loss narrows to $18.6 million; sales rise 40.8% to $2.3 million

Reuters04-01
Femasys FY25 net loss narrows to $18.6 million; sales rise 40.8% to $2.3 million
  • Femasys posted a net loss of $18.6 million, or $0.47 per share, for 2025.
  • Sales rose 40.8% to $2.3 million, primarily due to sales of FemBloc.
  • Operating loss narrowed to $17.6 million.
  • Cash and cash equivalents climbed to about $9.3 million, following $12 million financing.
  • Initiated patient enrollment in FemBloc FINALE pivotal trial, secured FDA 510(k) clearance for FemVue Controlled, and expects cash to fund operations into Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603311605PRIMZONEFULLFEED9681211) on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment